French pharmaceutical giant Sanofi (SNY, Financial) announced plans to establish a new factory in Singapore to enhance its capacity for producing vaccines and other medications, focusing on emergency preparedness for potential epidemics. The facility, named Modulus, will be located in the Tuas Biomedical Park and represents an investment of 800 million Singapore dollars (approximately $600 million).
The Modulus factory is designed to simultaneously produce up to four different vaccines or biopharmaceuticals. It is expected to be fully operational by mid-2026, creating 200 skilled jobs in Singapore. A significant feature of this facility is its modular design, allowing it to be reconfigured within days to switch between different technological platforms, a process that typically takes months or even years.
Brendan O'Callaghan, Sanofi's Executive Vice President of Manufacturing and Supply, highlighted that this modular approach enables the company to respond swiftly to public health challenges. Earlier this year, Sanofi completed a similar modular facility in France, emphasizing its commitment to innovative and flexible manufacturing solutions.
